US Patent Issued to AbelZeta on Sept. 29 for "Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof" (Chinese, American Inventors)

ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,747,279, issued on Sept. 29, was assigned to AbelZeta Inc. (Rockville, Md.).

"Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof" was invented by Yihong Yao (Rockville, Md.), Jiaqi Huang (Rockville, Md.), Shigui Zhu (Rockville, Md.), Wei Zhu (Rockville, Md.), Xin Yao (Rockville, Md.), Zhiyuan Li (Shanghai), Li Zhang (Rockville, Md.), Lin Zhu (Shanghai), Anyun Ma (Shanghai), Yutian Wei (Shanghai), Yanfeng Li (Shanghai), Qingxia Wang (Shanghai) and Jiaping He (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided are a chimeric antigen receptor targeting CD20 antigen and a...